This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More
by Zacks Equity Research
Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.
Bristol Myers (BMY) Zeposia Gets EC Nod for Ulcerative Colitis
by Zacks Equity Research
Bristol Myers (BMY) wins EC approval for Zeposia for a second indication ??? ulcerative colitis.
bluebird (BLUE) Filing for Thalassemia Therapy Gets Priority Review
by Zacks Equity Research
bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.
Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC
by Zacks Equity Research
Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.
Bristol Myers' (BMY) Cardiovascular Drug Review Extended by FDA
by Zacks Equity Research
Bristol Myers (BMY) announces extension of FDA review of its cardiovascular drug mavacamten. The new target action date is Apr 28, 2022.
Merck's (MRK) Keytruda Gets Approval for Certain RCC Patients
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers
by Zacks Equity Research
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
Compugen (CGEN) Stock Up on Bristol Myers' $20M Investment
by Zacks Equity Research
Compugen (CGEN) announces an expansion of its collaboration agreement with Bristol Myers Squibb and a $20 million equity investment by the latter.
Epizyme (EPZM) Q3 Loss Wider Than Expected, Revenues Up
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss in the third quarter and revenues miss estimates. Nevertheless, the pipeline progress is encouraging.
Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing
by Zacks Equity Research
Mirati's (MRTX) third-quarter earnings beat estimates. It initiates the NDA submission for adagrasib in second-line NSCLC. Shares rise in after-market trading.
bluebird (BLUE) Stock Down 19% on Q3 Earnings & Revenue Miss
by Zacks Equity Research
bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates. Shares decline 19% following the announcement.
FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.
Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Prothena misses on earnings and revenues in the third quarter of 2021. Nevertheless, the company's progress with its AD pipeline is encouraging.
Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3
by Zacks Equity Research
Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.
Amgen (AMGN) Q3 Earnings Top, Sales View Tightened, Stock Down
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for both earnings and sales. It lowers the upper end of the sales guidance for 2021 while raising the earnings range.
Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.
Pfizer (PFE) Q3 Earnings Top, COVID Vaccine Drives 2021 View Up
by Zacks Equity Research
Pfizer (PFE) beats third-quarter estimates for earnings and sales, and lifts guidance for 2021.
ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.
ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.
How Will Pfizer's (PFE) Key Drugs Impact Its Q3 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More
by Zacks Equity Research
Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
Q3 Earnings' Smooth Sailing Continues
by Mark Vickery
Several household-name companies have reported quarterly results. We also see an important economic print ahead of the bell.